In-hospital outcome of patients with acute coronary syndrome: relationship with inflammation and remodeling markers
- PMID: 17667031
- DOI: 10.2459/JCM.0b013e32802e6c28
In-hospital outcome of patients with acute coronary syndrome: relationship with inflammation and remodeling markers
Abstract
Objectives and methods: The present study was designed to evaluate the role of some inflammation [interleukin (IL)-1beta, soluble IL-1 receptor, IL-1 receptor antagonist (IL-1RA), high-sensitivity C-reactive protein (hsCRP) and fibrinogen], and remodeling markers [matrix metalloproteinase (MMP)-9, tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2] in patients with acute coronary syndrome (ACS; 40 patients), or chronic stable angina (CSA; 40 patients) compared to age- and sex-matched healthy controls (20 subjects).
Results: IL-1RA, hsCRP, fibrinogen, MMP-9, and TIMP-1 plasma levels were significantly higher in patients than in controls, whereas soluble IL-1 receptor had an opposite pattern. Among patients with ACS, hsCRP plasma levels were higher in patients with non-ST segment elevation myocardial infarction (NSTEMI) than in those with unstable angina (UA). TIMP-1 plasma levels were higher in those patients with ACS who did not respond to medical therapy (non-responsive unstable angina; NR-UA). A CRP plasma level higher than 0.86 mg/dl had a 91% positive predictive value (PPV) and 63% negative predictive value for NSTEMI (odds ratio = 6.4, 95% confidence interval = 1.5-27.4). TIMP-1 plasma level higher than 21.5 ng/ml had a 100% PPV for patients with NR-UA or NSTEMI. Binary logistic analysis confirmed TIMP-1 levels as being able to predict responsiveness to therapy.
Conclusions: In conclusion, a different biochemical pattern characterizes ACS patients: those with NR-UA show only an increase of remodeling markers, whereas ACS patients with NSTEMI have an increase of both remodeling and inflammation markers.
Similar articles
-
Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease.Am J Cardiol. 2010 Feb 15;105(4):429-34. doi: 10.1016/j.amjcard.2009.10.013. Epub 2010 Jan 5. Am J Cardiol. 2010. PMID: 20152234
-
Increased levels of interleukin-6 and matrix metalloproteinase-9 are of cardiac origin in acute coronary syndrome.Scand Cardiovasc J. 2007 Jun;41(3):149-54. doi: 10.1080/14017430601164263. Scand Cardiovasc J. 2007. PMID: 17487763
-
Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome.Am Heart J. 2001 Feb;141(2):211-7. doi: 10.1067/mhj.2001.112238. Am Heart J. 2001. PMID: 11174334
-
Risk stratifying the acute coronary syndrome patient: a focus on treatable risk.Rev Cardiovasc Med. 2007;8 Suppl 3:S3-8. Rev Cardiovasc Med. 2007. PMID: 17917619 Review.
-
[Markers of inflammatory process in stable and unstable coronary artery disease].Pol Merkur Lekarski. 2006 Jul;21(121):69-72. Pol Merkur Lekarski. 2006. PMID: 17007298 Review. Polish.
Cited by
-
Astaxanthin suppresses scavenger receptor expression and matrix metalloproteinase activity in macrophages.Eur J Nutr. 2010 Mar;49(2):119-26. doi: 10.1007/s00394-009-0056-4. Epub 2009 Sep 26. Eur J Nutr. 2010. PMID: 19784539
-
Modulation of high sensitivity C-reactive protein by soluble receptor for advanced glycation end products.Mol Cell Biochem. 2010 Aug;341(1-2):135-8. doi: 10.1007/s11010-010-0444-3. Epub 2010 Mar 27. Mol Cell Biochem. 2010. PMID: 20339904
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous